Glycaemic Variability in Haemodialysis
Research type
Research Study
Full title
A mixed method study of glucose instability, variability and exposure in insulin-treated diabetic individuals with established renal failure on haemodialysis. DRIVE - HD Study Diabetes and Real-world investigation of Instability Variability and Exposure in Haemodialysis
IRAS ID
212219
Contact name
Adam Kirk
Contact email
Sponsor organisation
Portsmouth Hospitals NHS Trust
ISRCTN Number
ISRCTN58101486
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Haemodialysis (HD) is a process whereby a person’s blood is passed through a machine to remove toxic waste products and fluid, functions failed kidneys are no longer able to. Diabetes is the leading cause of renal failure worldwide. Diabetes is growing not only a UK, but as global burden. The estimated UK prevalence is that 4 million are living with diabetes. The number affected has over doubled in the past 20 years and this is expected to continue to rise. People with diabetes are 3 times more like to need dialysis than the general population.
Those on HD with diabetes have reduced survival rates compared to those without diabetes, especially the younger patients. While large studies have resulted in evidenced based guidelines for diabetes monitoring and targets in the non-dialysis diabetic population to reduce risk and minimise complication the same cannot be said for the dialysis diabetic population.
Recent UK guidelines surrounding the management of diabetes in the haemodialysis unit have highlighted the need for individualised care in this high risk complex group of vulnerable patients. Therefore, the aim of this study is to use a novel device which will sample the level of interstitial glucose every fifteen minutes over a period of fourteen days to:
• Give a detailed individual ambulatory glucose profile.
• Examine the effect of the dialysis pattern to evaluate on the blood glucose profile.
• Gain valuable insight as to the patient perspective of diabetes management when in renal failure and experience of the device during the monitoring period.It is hoped, that this study will provide a greater understanding of the utility of continuous monitoring devises while evaluating glucose instability, variability and exposure in patients with established renal failure in; order to look at methods of optimising control, improving not only patient outcomes but patient experiences.
REC name
London - Westminster Research Ethics Committee
REC reference
17/LO/0131
Date of REC Opinion
3 Mar 2017
REC opinion
Further Information Favourable Opinion